INFO & CONTACTS:  +39 02 2390 1

A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors

Phase: Phase I clinical trials

Principal Investigator: Dott. Duca Matteo

Main Facility: Oncologia Medica 1

Drug: BAY 3713372

Pathologies: Lung cancer

ClinicalTrials.gov: Read the details about clinical trials

A first-in-man study with BAY 3713372, an oral protein arginine N-methyltransferase 5 (PRMT5) inhibitor, in adults with MTAP-deleted solid tumors. 

The study comprises a dose escalation phase which will evaluate the safety and tolerability of BAY 3713372 administered as monotherapy. Dose escalation will be followed by a cohort expansion phase, evaluating the preliminary anti-tumor activity of BAY 3713372. 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe